-
1
-
-
0022499547
-
Complementary DNA for a novel human interleukin (BSF-2) that induces B lymphocytes to produce immunoglobulin
-
T. Hirano, K. Yasukawa, H. Harada, T. Taga, Y. Watanabe, T. Matsuda, and et al. Complementary DNA for a novel human interleukin (BSF-2) that induces B lymphocytes to produce immunoglobulin Nature 324 1986 73 76
-
(1986)
Nature
, vol.324
, pp. 73-76
-
-
Hirano, T.1
Yasukawa, K.2
Harada, H.3
Taga, T.4
Watanabe, Y.5
Matsuda, T.6
-
2
-
-
17644368573
-
Interleukin-6: From basic science to medicine - 40 years in immunology
-
T. Kishimoto Interleukin-6: from basic science to medicine - 40 years in immunology Annu. Rev. Immunol. 23 2005 1 21
-
(2005)
Annu. Rev. Immunol.
, vol.23
, pp. 1-21
-
-
Kishimoto, T.1
-
4
-
-
51349133256
-
Interleukin-6 regulates pancreatic alpha-cell mass expansion
-
H. Ellingsgaard, J.A. Ehses, E.B. Hammar, L. Van Lommel, R. Quintens, G. Martens, and et al. Interleukin-6 regulates pancreatic alpha-cell mass expansion Proc. Natl. Acad. Sci. U. S. A. 105 2008 13163 13168
-
(2008)
Proc. Natl. Acad. Sci. U. S. A.
, vol.105
, pp. 13163-13168
-
-
Ellingsgaard, H.1
Ehses, J.A.2
Hammar, E.B.3
Van Lommel, L.4
Quintens, R.5
Martens, G.6
-
5
-
-
0029863504
-
The function of the soluble interleukin 6 (IL-6) receptor in vivo: Sensitization of human soluble IL-6 receptor transgenic mice towards IL-6 and prolongation of the plasma half-life of IL-6
-
M. Peters, S. Jacobs, M. Ehlers, P. Vollmer, J. Mullberg, E. Wolf, and et al. The function of the soluble interleukin 6 (IL-6) receptor in vivo: sensitization of human soluble IL-6 receptor transgenic mice towards IL-6 and prolongation of the plasma half-life of IL-6 J. Exp. Med. 183 1996 1399 1406
-
(1996)
J. Exp. Med.
, vol.183
, pp. 1399-1406
-
-
Peters, M.1
Jacobs, S.2
Ehlers, M.3
Vollmer, P.4
Mullberg, J.5
Wolf, E.6
-
6
-
-
84917744236
-
Antigen presenting cell-derived IL-6 restricts Th2-cell differentiation
-
A. Mayer, D. Debuisson, S. Denanglaire, F. Eddahri, L. Fievez, M. Hercor, and et al. Antigen presenting cell-derived IL-6 restricts Th2-cell differentiation Eur. J. Immunol. 44 2014 3252 3262
-
(2014)
Eur. J. Immunol.
, vol.44
, pp. 3252-3262
-
-
Mayer, A.1
Debuisson, D.2
Denanglaire, S.3
Eddahri, F.4
Fievez, L.5
Hercor, M.6
-
7
-
-
84866749073
-
Defining the human T helper 17 cell phenotype
-
F. Annunziato, L. Cosmi, F. Liotta, E. Maggi, and S. Romagnani Defining the human T helper 17 cell phenotype Trends Immunol. 33 2012 505 512
-
(2012)
Trends Immunol.
, vol.33
, pp. 505-512
-
-
Annunziato, F.1
Cosmi, L.2
Liotta, F.3
Maggi, E.4
Romagnani, S.5
-
8
-
-
84906535154
-
The IL-23-IL-17 immune axis: From mechanisms to therapeutic testing
-
S.L. Gaffen, R. Jain, A.V. Garg, and D.J. Cua The IL-23-IL-17 immune axis: from mechanisms to therapeutic testing Nat. Rev. Immunol. 14 2014 585 600
-
(2014)
Nat. Rev. Immunol.
, vol.14
, pp. 585-600
-
-
Gaffen, S.L.1
Jain, R.2
Garg, A.V.3
Cua, D.J.4
-
9
-
-
33646577466
-
Reciprocal developmental pathways for the generation of pathogenic effector TH17 and regulatory T cells
-
E. Bettelli, Y. Carrier, W. Gao, T. Korn, T.B. Strom, M. Oukka, and et al. Reciprocal developmental pathways for the generation of pathogenic effector TH17 and regulatory T cells Nature 441 2006 235 238
-
(2006)
Nature
, vol.441
, pp. 235-238
-
-
Bettelli, E.1
Carrier, Y.2
Gao, W.3
Korn, T.4
Strom, T.B.5
Oukka, M.6
-
10
-
-
57349083145
-
Interleukin-6 blockade suppresses autoimmune arthritis in mice by the inhibition of inflammatory Th17 responses
-
M. Fujimoto, S. Serada, M. Mihara, Y. Uchiyama, H. Yoshida, N. Koike, and et al. Interleukin-6 blockade suppresses autoimmune arthritis in mice by the inhibition of inflammatory Th17 responses Arthritis Rheum. 58 2008 3710 3719
-
(2008)
Arthritis Rheum.
, vol.58
, pp. 3710-3719
-
-
Fujimoto, M.1
Serada, S.2
Mihara, M.3
Uchiyama, Y.4
Yoshida, H.5
Koike, N.6
-
11
-
-
0037363585
-
Immunoregulation in the tissues by gammadelta T cells
-
A. Hayday, and R. Tigelaar Immunoregulation in the tissues by gammadelta T cells Nat. Rev. Immunol. 3 2003 233 242
-
(2003)
Nat. Rev. Immunol.
, vol.3
, pp. 233-242
-
-
Hayday, A.1
Tigelaar, R.2
-
12
-
-
77954143695
-
Innate IL-17-producing cells: The sentinels of the immune system
-
D.J. Cua, and C.M. Tato Innate IL-17-producing cells: the sentinels of the immune system Nat. Rev. Immunol. 10 2010 479 489
-
(2010)
Nat. Rev. Immunol.
, vol.10
, pp. 479-489
-
-
Cua, D.J.1
Tato, C.M.2
-
13
-
-
80052734905
-
Interleukin-17 accelerates allograft rejection by suppressing regulatory T cell expansion
-
S. Itoh, N. Kimura, R.C. Axtell, J.B. Velotta, Y. Gong, X. Wang, and et al. Interleukin-17 accelerates allograft rejection by suppressing regulatory T cell expansion Circulation 124 2011 S187 S196
-
(2011)
Circulation
, vol.124
, pp. S187-S196
-
-
Itoh, S.1
Kimura, N.2
Axtell, R.C.3
Velotta, J.B.4
Gong, Y.5
Wang, X.6
-
14
-
-
79960119130
-
Differentiation, phenotype, and function of interleukin-17-producing human Vgamma9Vdelta2 T cells
-
N. Caccamo, C. La Mendola, V. Orlando, S. Meraviglia, M. Todaro, G. Stassi, and et al. Differentiation, phenotype, and function of interleukin-17-producing human Vgamma9Vdelta2 T cells Blood 118 2011 129 138
-
(2011)
Blood
, vol.118
, pp. 129-138
-
-
Caccamo, N.1
La Mendola, C.2
Orlando, V.3
Meraviglia, S.4
Todaro, M.5
Stassi, G.6
-
15
-
-
81455135808
-
Prostaglandin I(2)promotes the development of IL-17-producing gammadelta T cells that associate with the epithelium during allergic lung inflammation
-
Z. Jaffar, M.E. Ferrini, P.K. Shaw, G.A. FitzGerald, and K. Roberts Prostaglandin I(2)promotes the development of IL-17-producing gammadelta T cells that associate with the epithelium during allergic lung inflammation J. Immunol. 187 2011 5380 5391
-
(2011)
J. Immunol.
, vol.187
, pp. 5380-5391
-
-
Jaffar, Z.1
Ferrini, M.E.2
Shaw, P.K.3
FitzGerald, G.A.4
Roberts, K.5
-
16
-
-
84897952509
-
Treg functional stability and its responsiveness to the microenvironment
-
J. Barbi, D. Pardoll, and F. Pan Treg functional stability and its responsiveness to the microenvironment Immunol. Rev. 259 2014 115 139
-
(2014)
Immunol. Rev.
, vol.259
, pp. 115-139
-
-
Barbi, J.1
Pardoll, D.2
Pan, F.3
-
17
-
-
77954096689
-
IL-6: Regulator of Treg/Th17 balance
-
A. Kimura, and T. Kishimoto IL-6: regulator of Treg/Th17 balance Eur. J. Immunol. 40 2010 1830 1835
-
(2010)
Eur. J. Immunol.
, vol.40
, pp. 1830-1835
-
-
Kimura, A.1
Kishimoto, T.2
-
18
-
-
0028675983
-
Interleukin-6 is required in vivo for the regulation of stem cells and committed progenitors of the hematopoietic system
-
A. Bernad, M. Kopf, R. Kulbacki, N. Weich, G. Koehler, and J.C. Gutierrez-Ramos Interleukin-6 is required in vivo for the regulation of stem cells and committed progenitors of the hematopoietic system Immunity 1 1994 725 731
-
(1994)
Immunity
, vol.1
, pp. 725-731
-
-
Bernad, A.1
Kopf, M.2
Kulbacki, R.3
Weich, N.4
Koehler, G.5
Gutierrez-Ramos, J.C.6
-
19
-
-
81255189474
-
IL-6 controls leukemic multipotent progenitor cell fate and contributes to chronic myelogenous leukemia development
-
D. Reynaud, E. Pietras, K. Barry-Holson, A. Mir, M. Binnewies, M. Jeanne, and et al. IL-6 controls leukemic multipotent progenitor cell fate and contributes to chronic myelogenous leukemia development Cancer Cell 20 2011 661 673
-
(2011)
Cancer Cell
, vol.20
, pp. 661-673
-
-
Reynaud, D.1
Pietras, E.2
Barry-Holson, K.3
Mir, A.4
Binnewies, M.5
Jeanne, M.6
-
20
-
-
84864744709
-
Context-specific roles for paracrine IL-6 in lymphomagenesis
-
L.A. Gilbert, and M.T. Hemann Context-specific roles for paracrine IL-6 in lymphomagenesis Genes Dev. 26 2012 1758 1768
-
(2012)
Genes Dev.
, vol.26
, pp. 1758-1768
-
-
Gilbert, L.A.1
Hemann, M.T.2
-
21
-
-
77949322552
-
Autoimmune disease in Lyn-deficient mice is dependent on an inflammatory environment established by IL-6
-
E. Tsantikos, S.A. Oracki, C. Quilici, G.P. Anderson, D.M. Tarlinton, and M.L. Hibbs Autoimmune disease in Lyn-deficient mice is dependent on an inflammatory environment established by IL-6 J. Immunol. 184 2010 1348 1360
-
(2010)
J. Immunol.
, vol.184
, pp. 1348-1360
-
-
Tsantikos, E.1
Oracki, S.A.2
Quilici, C.3
Anderson, G.P.4
Tarlinton, D.M.5
Hibbs, M.L.6
-
22
-
-
0029999725
-
Is IL-6 both a cytokine and a neurotrophic factor?
-
J.A. Wagner Is IL-6 both a cytokine and a neurotrophic factor? J. Exp. Med. 183 1996 2417 2419
-
(1996)
J. Exp. Med.
, vol.183
, pp. 2417-2419
-
-
Wagner, J.A.1
-
23
-
-
0032534730
-
IL-6-deficient mice are resistant to experimental autoimmune encephalomyelitis: Roles of IL-6 in the activation and differentiation of autoreactive T cells
-
E.B. Samoilova, J.L. Horton, B. Hilliard, T.S. Liu, and Y. Chen IL-6-deficient mice are resistant to experimental autoimmune encephalomyelitis: roles of IL-6 in the activation and differentiation of autoreactive T cells J. Immunol. 161 1998 6480 6486
-
(1998)
J. Immunol.
, vol.161
, pp. 6480-6486
-
-
Samoilova, E.B.1
Horton, J.L.2
Hilliard, B.3
Liu, T.S.4
Chen, Y.5
-
24
-
-
84863803849
-
B cell depletion therapy ameliorates autoimmune disease through ablation of IL-6-producing B cells
-
T.A. Barr, P. Shen, S. Brown, V. Lampropoulou, T. Roch, S. Lawrie, and et al. B cell depletion therapy ameliorates autoimmune disease through ablation of IL-6-producing B cells J. Exp. Med. 209 2012 1001 1010
-
(2012)
J. Exp. Med.
, vol.209
, pp. 1001-1010
-
-
Barr, T.A.1
Shen, P.2
Brown, S.3
Lampropoulou, V.4
Roch, T.5
Lawrie, S.6
-
25
-
-
79952762854
-
Interleukin 6 signaling promotes anti-aquaporin 4 autoantibody production from plasmablasts in neuromyelitis optica
-
N. Chihara, T. Aranami, W. Sato, Y. Miyazaki, S. Miyake, T. Okamoto, and et al. Interleukin 6 signaling promotes anti-aquaporin 4 autoantibody production from plasmablasts in neuromyelitis optica Proc. Natl. Acad. Sci. U. S. A. 108 2011 3701 3706
-
(2011)
Proc. Natl. Acad. Sci. U. S. A.
, vol.108
, pp. 3701-3706
-
-
Chihara, N.1
Aranami, T.2
Sato, W.3
Miyazaki, Y.4
Miyake, S.5
Okamoto, T.6
-
26
-
-
84924588068
-
Cutting edge: Circulating plasmablasts induce the differentiation of human T follicular helper cells via IL-6 production
-
K.M. Chavele, E. Merry, and M.R. Ehrenstein Cutting edge: circulating plasmablasts induce the differentiation of human T follicular helper cells via IL-6 production J. Immunol. 194 2015 2482 2485
-
(2015)
J. Immunol.
, vol.194
, pp. 2482-2485
-
-
Chavele, K.M.1
Merry, E.2
Ehrenstein, M.R.3
-
27
-
-
0025275703
-
Constitutive production of interleukin-6 and immunologic features in cardiac myxomas
-
M. Jourdan, R. Bataille, J. Seguin, X.G. Zhang, P.A. Chaptal, and B. Klein Constitutive production of interleukin-6 and immunologic features in cardiac myxomas Arthritis Rheum. 33 1990 398 402
-
(1990)
Arthritis Rheum.
, vol.33
, pp. 398-402
-
-
Jourdan, M.1
Bataille, R.2
Seguin, J.3
Zhang, X.G.4
Chaptal, P.A.5
Klein, B.6
-
28
-
-
84895519112
-
Protein kinase C isoforms in atherosclerosis: Pro- or anti-inflammatory?
-
H.C. Fan, C. Fernandez-Hernando, and J.H. Lai Protein kinase C isoforms in atherosclerosis: pro- or anti-inflammatory? Biochem. Pharmacol. 88 2014 139 149
-
(2014)
Biochem. Pharmacol.
, vol.88
, pp. 139-149
-
-
Fan, H.C.1
Fernandez-Hernando, C.2
Lai, J.H.3
-
29
-
-
43249118045
-
Long-term interleukin-6 levels and subsequent risk of coronary heart disease: Two new prospective studies and a systematic review
-
J. Danesh, S. Kaptoge, A.G. Mann, N. Sarwar, A. Wood, S.B. Angleman, and et al. Long-term interleukin-6 levels and subsequent risk of coronary heart disease: two new prospective studies and a systematic review PLoS Med. 5 2008 e78
-
(2008)
PLoS Med.
, vol.5
, pp. e78
-
-
Danesh, J.1
Kaptoge, S.2
Mann, A.G.3
Sarwar, N.4
Wood, A.5
Angleman, S.B.6
-
30
-
-
0037458105
-
Interleukin-6-deficient mice resist development of autoimmune myocarditis associated with impaired upregulation of complement C3
-
U. Eriksson, M.O. Kurrer, N. Schmitz, S.C. Marsch, A. Fontana, H.P. Eugster, and et al. Interleukin-6-deficient mice resist development of autoimmune myocarditis associated with impaired upregulation of complement C3 Circulation 107 2003 320 325
-
(2003)
Circulation
, vol.107
, pp. 320-325
-
-
Eriksson, U.1
Kurrer, M.O.2
Schmitz, N.3
Marsch, S.C.4
Fontana, A.5
Eugster, H.P.6
-
31
-
-
84860524460
-
Macrophage-stimulated cardiac fibroblast production of IL-6 is essential for TGF beta/Smad activation and cardiac fibrosis induced by angiotensin II
-
F. Ma, Y. Li, L. Jia, Y. Han, J. Cheng, H. Li, and et al. Macrophage-stimulated cardiac fibroblast production of IL-6 is essential for TGF beta/Smad activation and cardiac fibrosis induced by angiotensin II PLOS ONE 7 2012 e35144
-
(2012)
PLOS ONE
, vol.7
, pp. e35144
-
-
Ma, F.1
Li, Y.2
Jia, L.3
Han, Y.4
Cheng, J.5
Li, H.6
-
32
-
-
84930177360
-
The varying faces of IL-6: From cardiac protection to cardiac failure
-
J.A. Fontes, N.R. Rose, and D. Cihakova The varying faces of IL-6: from cardiac protection to cardiac failure Cytokine 2015 10.1016/j.cyto.2014.12.024
-
(2015)
Cytokine
-
-
Fontes, J.A.1
Rose, N.R.2
Cihakova, D.3
-
33
-
-
69949138556
-
IL-6 during viral-induced chronic autoimmune myocarditis
-
M.C. Poffenberger, and M.S. Horwitz IL-6 during viral-induced chronic autoimmune myocarditis Ann. N. Y. Acad. Sci. 1173 2009 318 325
-
(2009)
Ann. N. Y. Acad. Sci.
, vol.1173
, pp. 318-325
-
-
Poffenberger, M.C.1
Horwitz, M.S.2
-
34
-
-
84869834766
-
Role of IL-6 in asthma and other inflammatory pulmonary diseases
-
M. Rincon, and C.G. Irvin Role of IL-6 in asthma and other inflammatory pulmonary diseases Int. J. Biol. Sci. 8 2012 1281 1290
-
(2012)
Int. J. Biol. Sci.
, vol.8
, pp. 1281-1290
-
-
Rincon, M.1
Irvin, C.G.2
-
35
-
-
84896317905
-
IL-6/Stat3-driven pulmonary inflammation, but not emphysema, is dependent on interleukin-17A in mice
-
S.M. Ruwanpura, L. McLeod, G.D. Brooks, S. Bozinovski, R. Vlahos, A. Longano, and et al. IL-6/Stat3-driven pulmonary inflammation, but not emphysema, is dependent on interleukin-17A in mice Respirology 19 2014 419 427
-
(2014)
Respirology
, vol.19
, pp. 419-427
-
-
Ruwanpura, S.M.1
McLeod, L.2
Brooks, G.D.3
Bozinovski, S.4
Vlahos, R.5
Longano, A.6
-
36
-
-
0032737345
-
Role of IL-6 in the pleurisy and lung injury caused by carrageenan
-
S. Cuzzocrea, L. Sautebin, G. De Sarro, G. Costantino, L. Rombola, E. Mazzon, and et al. Role of IL-6 in the pleurisy and lung injury caused by carrageenan J. Immunol. 163 1999 5094 5104
-
(1999)
J. Immunol.
, vol.163
, pp. 5094-5104
-
-
Cuzzocrea, S.1
Sautebin, L.2
De Sarro, G.3
Costantino, G.4
Rombola, L.5
Mazzon, E.6
-
37
-
-
84874606609
-
IL-6 trans-signaling promotes pancreatitis-associated lung injury and lethality
-
H. Zhang, P. Neuhofer, L. Song, B. Rabe, M. Lesina, M.U. Kurkowski, and et al. IL-6 trans-signaling promotes pancreatitis-associated lung injury and lethality J. Clin. Invest. 123 2013 1019 1031
-
(2013)
J. Clin. Invest.
, vol.123
, pp. 1019-1031
-
-
Zhang, H.1
Neuhofer, P.2
Song, L.3
Rabe, B.4
Lesina, M.5
Kurkowski, M.U.6
-
38
-
-
84927511163
-
Lung parenchyma-derived IL-6 promotes IL-17A-dependent acute lung injury after allogeneic stem cell transplantation
-
A. Varelias, K.H. Gartlan, E. Kreijveld, S.D. Olver, M. Lor, R.D. Kuns, and et al. Lung parenchyma-derived IL-6 promotes IL-17A-dependent acute lung injury after allogeneic stem cell transplantation Blood 125 2015 2435 2444
-
(2015)
Blood
, vol.125
, pp. 2435-2444
-
-
Varelias, A.1
Gartlan, K.H.2
Kreijveld, E.3
Olver, S.D.4
Lor, M.5
Kuns, R.D.6
-
39
-
-
16844387413
-
The IL-6-gp130-STAT3 pathway in hepatocytes triggers liver protection in T cell-mediated liver injury
-
C. Klein, T. Wustefeld, U. Assmus, T. Roskams, S. Rose-John, M. Muller, and et al. The IL-6-gp130-STAT3 pathway in hepatocytes triggers liver protection in T cell-mediated liver injury J. Clin. Invest. 115 2005 860 869
-
(2005)
J. Clin. Invest.
, vol.115
, pp. 860-869
-
-
Klein, C.1
Wustefeld, T.2
Assmus, U.3
Roskams, T.4
Rose-John, S.5
Muller, M.6
-
40
-
-
84899767448
-
Synthesis of IL-6 by hepatocytes is a normal response to common hepatic stimuli
-
C.A. Norris, M. He, L.I. Kang, M.Q. Ding, J.E. Radder, M.M. Haynes, and et al. Synthesis of IL-6 by hepatocytes is a normal response to common hepatic stimuli PLOS ONE 9 2014 e96053
-
(2014)
PLOS ONE
, vol.9
, pp. e96053
-
-
Norris, C.A.1
He, M.2
Kang, L.I.3
Ding, M.Q.4
Radder, J.E.5
Haynes, M.M.6
-
41
-
-
84864398664
-
DEC1 binding to the proximal promoter of CYP3A4 ascribes to the downregulation of CYP3A4 expression by IL-6 in primary human hepatocytes
-
Z. Mao, X. Luan, G. Cao, W. Liu, J. Xiong, G. Hu, and et al. DEC1 binding to the proximal promoter of CYP3A4 ascribes to the downregulation of CYP3A4 expression by IL-6 in primary human hepatocytes Biochem. Pharmacol. 84 2012 701 711
-
(2012)
Biochem. Pharmacol.
, vol.84
, pp. 701-711
-
-
Mao, Z.1
Luan, X.2
Cao, G.3
Liu, W.4
Xiong, J.5
Hu, G.6
-
42
-
-
0029934454
-
IL-6-deficient mice exhibit normal mucosal IgA responses to local immunizations and Helicobacter felis infection
-
A.K. Bromander, L. Ekman, M. Kopf, J.G. Nedrud, and N.Y. Lycke IL-6-deficient mice exhibit normal mucosal IgA responses to local immunizations and Helicobacter felis infection J. Immunol. 156 1996 4290 4297
-
(1996)
J. Immunol.
, vol.156
, pp. 4290-4297
-
-
Bromander, A.K.1
Ekman, L.2
Kopf, M.3
Nedrud, J.G.4
Lycke, N.Y.5
-
43
-
-
77149155643
-
Disease-related expression of the IL6/STAT3/SOCS3 signalling pathway in ulcerative colitis and ulcerative colitis-related carcinogenesis
-
Y. Li, C. de Haar, M. Chen, J. Deuring, M.M. Gerrits, R. Smits, and et al. Disease-related expression of the IL6/STAT3/SOCS3 signalling pathway in ulcerative colitis and ulcerative colitis-related carcinogenesis Gut 59 2010 227 235
-
(2010)
Gut
, vol.59
, pp. 227-235
-
-
Li, Y.1
De Haar, C.2
Chen, M.3
Deuring, J.4
Gerrits, M.M.5
Smits, R.6
-
44
-
-
18344410191
-
Blockade of interleukin 6 trans signaling suppresses T-cell resistance against apoptosis in chronic intestinal inflammation: Evidence in Crohn disease and experimental colitis in vivo
-
R. Atreya, J. Mudter, S. Finotto, J. Mullberg, T. Jostock, S. Wirtz, and et al. Blockade of interleukin 6 trans signaling suppresses T-cell resistance against apoptosis in chronic intestinal inflammation: evidence in Crohn disease and experimental colitis in vivo Nat. Med. 6 2000 583 588
-
(2000)
Nat. Med.
, vol.6
, pp. 583-588
-
-
Atreya, R.1
Mudter, J.2
Finotto, S.3
Mullberg, J.4
Jostock, T.5
Wirtz, S.6
-
45
-
-
84918522920
-
IL-6 stimulates intestinal epithelial proliferation and repair after injury
-
K.A. Kuhn, N.A. Manieri, T.C. Liu, and T.S. Stappenbeck IL-6 stimulates intestinal epithelial proliferation and repair after injury PLOS ONE 9 2014 e114195
-
(2014)
PLOS ONE
, vol.9
, pp. e114195
-
-
Kuhn, K.A.1
Manieri, N.A.2
Liu, T.C.3
Stappenbeck, T.S.4
-
46
-
-
73649123508
-
Interleukin 6 (IL-6) deficiency delays lupus nephritis in MRL-Faslpr mice: The IL-6 pathway as a new therapeutic target in treatment of autoimmune kidney disease in systemic lupus erythematosus
-
H. Cash, M. Relle, J. Menke, C. Brochhausen, S.A. Jones, N. Topley, and et al. Interleukin 6 (IL-6) deficiency delays lupus nephritis in MRL-Faslpr mice: the IL-6 pathway as a new therapeutic target in treatment of autoimmune kidney disease in systemic lupus erythematosus J. Rheumatol. 37 2010 60 70
-
(2010)
J. Rheumatol.
, vol.37
, pp. 60-70
-
-
Cash, H.1
Relle, M.2
Menke, J.3
Brochhausen, C.4
Jones, S.A.5
Topley, N.6
-
47
-
-
84885126530
-
Interleukin-6 trans-signaling exacerbates inflammation and renal pathology in lupus-prone mice
-
E. Tsantikos, M.J. Maxwell, T. Putoczki, M. Ernst, S. Rose-John, D.M. Tarlinton, and et al. Interleukin-6 trans-signaling exacerbates inflammation and renal pathology in lupus-prone mice Arthritis Rheum. 65 2013 2691 2702
-
(2013)
Arthritis Rheum.
, vol.65
, pp. 2691-2702
-
-
Tsantikos, E.1
Maxwell, M.J.2
Putoczki, T.3
Ernst, M.4
Rose-John, S.5
Tarlinton, D.M.6
-
48
-
-
84924580495
-
Inflammation-induced IL-6 functions as a natural brake on macrophages and limits GN
-
M. Luig, M.A. Kluger, B. Goerke, M. Meyer, A. Nosko, I. Yan, and et al. Inflammation-induced IL-6 functions as a natural brake on macrophages and limits GN J. Am. Soc. Nephrol. 2015 10.1681/ASN.2014060620
-
(2015)
J. Am. Soc. Nephrol.
-
-
Luig, M.1
Kluger, M.A.2
Goerke, B.3
Meyer, M.4
Nosko, A.5
Yan, I.6
-
49
-
-
84904558110
-
IL-6 in diabetes and cardiovascular complications
-
D. Qu, J. Liu, C.W. Lau, and Y. Huang IL-6 in diabetes and cardiovascular complications Br. J. Pharmacol. 171 2014 3595 3603
-
(2014)
Br. J. Pharmacol.
, vol.171
, pp. 3595-3603
-
-
Qu, D.1
Liu, J.2
Lau, C.W.3
Huang, Y.4
-
50
-
-
84908161000
-
Revisiting STAT3 signalling in cancer: New and unexpected biological functions
-
H. Yu, H. Lee, A. Herrmann, R. Buettner, and R. Jove Revisiting STAT3 signalling in cancer: new and unexpected biological functions Nat. Rev. Cancer 14 2014 736 746
-
(2014)
Nat. Rev. Cancer
, vol.14
, pp. 736-746
-
-
Yu, H.1
Lee, H.2
Herrmann, A.3
Buettner, R.4
Jove, R.5
-
51
-
-
0028805674
-
Enhancement of transformation in vitro of a nontumorigenic rat urothelial cell line by interleukin 6
-
M. Okamoto, H. Kawamata, K. Kawai, and R. Oyasu Enhancement of transformation in vitro of a nontumorigenic rat urothelial cell line by interleukin 6 Cancer Res. 55 1995 4581 4585
-
(1995)
Cancer Res.
, vol.55
, pp. 4581-4585
-
-
Okamoto, M.1
Kawamata, H.2
Kawai, K.3
Oyasu, R.4
-
52
-
-
36849039660
-
IL-6 triggers malignant features in mammospheres from human ductal breast carcinoma and normal mammary gland
-
P. Sansone, G. Storci, S. Tavolari, T. Guarnieri, C. Giovannini, M. Taffurelli, and et al. IL-6 triggers malignant features in mammospheres from human ductal breast carcinoma and normal mammary gland J. Clin. Invest. 117 2007 3988 4002
-
(2007)
J. Clin. Invest.
, vol.117
, pp. 3988-4002
-
-
Sansone, P.1
Storci, G.2
Tavolari, S.3
Guarnieri, T.4
Giovannini, C.5
Taffurelli, M.6
-
53
-
-
84877040826
-
Enhanced IL-6/IL-6R signaling promotes growth and malignant properties in EBV-infected premalignant and cancerous nasopharyngeal epithelial cells
-
G. Zhang, C.M. Tsang, W. Deng, Y.L. Yip, V.W. Lui, S.C. Wong, and et al. Enhanced IL-6/IL-6R signaling promotes growth and malignant properties in EBV-infected premalignant and cancerous nasopharyngeal epithelial cells PLOS ONE 8 2013 e62284
-
(2013)
PLOS ONE
, vol.8
, pp. e62284
-
-
Zhang, G.1
Tsang, C.M.2
Deng, W.3
Yip, Y.L.4
Lui, V.W.5
Wong, S.C.6
-
54
-
-
58649108302
-
IL-6 and Stat3 are required for survival of intestinal epithelial cells and development of colitis-associated cancer
-
S. Grivennikov, E. Karin, J. Terzic, D. Mucida, G.Y. Yu, S. Vallabhapurapu, and et al. IL-6 and Stat3 are required for survival of intestinal epithelial cells and development of colitis-associated cancer Cancer Cell 15 2009 103 113
-
(2009)
Cancer Cell
, vol.15
, pp. 103-113
-
-
Grivennikov, S.1
Karin, E.2
Terzic, J.3
Mucida, D.4
Yu, G.Y.5
Vallabhapurapu, S.6
-
55
-
-
84882714320
-
JAK-STAT blockade inhibits tumor initiation and clonogenic recovery of prostate cancer stem-like cells
-
P. Kroon, P.A. Berry, M.J. Stower, G. Rodrigues, V.M. Mann, M. Simms, and et al. JAK-STAT blockade inhibits tumor initiation and clonogenic recovery of prostate cancer stem-like cells Cancer Res. 73 2013 5288 5298
-
(2013)
Cancer Res.
, vol.73
, pp. 5288-5298
-
-
Kroon, P.1
Berry, P.A.2
Stower, M.J.3
Rodrigues, G.4
Mann, V.M.5
Simms, M.6
-
56
-
-
84939572294
-
Biomechanical and biochemical remodeling of stromal extracellular matrix in cancer
-
R. Malik, P.I. Lelkes, and E. Cukierman Biomechanical and biochemical remodeling of stromal extracellular matrix in cancer Trends Biotechnol. 33 2015 230 236
-
(2015)
Trends Biotechnol.
, vol.33
, pp. 230-236
-
-
Malik, R.1
Lelkes, P.I.2
Cukierman, E.3
-
57
-
-
84938199098
-
IL-6 originated from breast cancer tissue-derived mesenchymal stromal cells may contribute to carcinogenesis
-
O. Saglam, Z.S. Unal, C. Subasi, E. Ulukaya, and E. Karaoz IL-6 originated from breast cancer tissue-derived mesenchymal stromal cells may contribute to carcinogenesis Tumour Biol. 2015 10.1007/s13277-015-3241-5
-
(2015)
Tumour Biol.
-
-
Saglam, O.1
Unal, Z.S.2
Subasi, C.3
Ulukaya, E.4
Karaoz, E.5
-
58
-
-
84892917277
-
Interleukin-6 released by colon cancer-associated fibroblasts is critical for tumour angiogenesis: Anti-interleukin-6 receptor antibody suppressed angiogenesis and inhibited tumour-stroma interaction
-
T. Nagasaki, M. Hara, H. Nakanishi, H. Takahashi, M. Sato, and H. Takeyama Interleukin-6 released by colon cancer-associated fibroblasts is critical for tumour angiogenesis: anti-interleukin-6 receptor antibody suppressed angiogenesis and inhibited tumour-stroma interaction Br. J. Cancer 110 2014 469 478
-
(2014)
Br. J. Cancer
, vol.110
, pp. 469-478
-
-
Nagasaki, T.1
Hara, M.2
Nakanishi, H.3
Takahashi, H.4
Sato, M.5
Takeyama, H.6
-
59
-
-
84920653683
-
The tumor microenvironment is the main source of IL-6 for plasma cell tumor development in mice
-
T.R. Rosean, V.S. Tompkins, A.K. Olivier, R. Sompallae, L.A. Norian, H.C. Morse 3rd, and et al. The tumor microenvironment is the main source of IL-6 for plasma cell tumor development in mice Leukemia 29 2015 233 237
-
(2015)
Leukemia
, vol.29
, pp. 233-237
-
-
Rosean, T.R.1
Tompkins, V.S.2
Olivier, A.K.3
Sompallae, R.4
Norian, L.A.5
Morse, H.C.6
-
60
-
-
84909607972
-
The cytokine IL-6 reactivates breast stromal fibroblasts through transcription factor STAT3-dependent up-regulation of the RNA-binding protein AUF1
-
S.F. Hendrayani, H.H. Al-Khalaf, and A. Aboussekhra The cytokine IL-6 reactivates breast stromal fibroblasts through transcription factor STAT3-dependent up-regulation of the RNA-binding protein AUF1 J. Biol. Chem. 289 2014 30962 30976
-
(2014)
J. Biol. Chem.
, vol.289
, pp. 30962-30976
-
-
Hendrayani, S.F.1
Al-Khalaf, H.H.2
Aboussekhra, A.3
-
61
-
-
84900035813
-
Activation of a positive feedback loop involving IL-6 and aromatase promotes intratumoral 17beta-estradiol biosynthesis in endometrial carcinoma microenvironment
-
Q. Che, B.Y. Liu, Y. Liao, H.J. Zhang, T.T. Yang, Y.Y. He, and et al. Activation of a positive feedback loop involving IL-6 and aromatase promotes intratumoral 17beta-estradiol biosynthesis in endometrial carcinoma microenvironment Int. J. Cancer 135 2014 282 294
-
(2014)
Int. J. Cancer
, vol.135
, pp. 282-294
-
-
Che, Q.1
Liu, B.Y.2
Liao, Y.3
Zhang, H.J.4
Yang, T.T.5
He, Y.Y.6
-
62
-
-
84894593599
-
Molecular mechanisms of epithelial-mesenchymal transition
-
S. Lamouille, J. Xu, and R. Derynck Molecular mechanisms of epithelial-mesenchymal transition Nat. Rev. Mol. Cell Biol. 15 2014 178 196
-
(2014)
Nat. Rev. Mol. Cell Biol.
, vol.15
, pp. 178-196
-
-
Lamouille, S.1
Xu, J.2
Derynck, R.3
-
63
-
-
69249221254
-
Interleukin-6 induces an epithelial-mesenchymal transition phenotype in human breast cancer cells
-
N.J. Sullivan, A.K. Sasser, A.E. Axel, F. Vesuna, V. Raman, N. Ramirez, and et al. Interleukin-6 induces an epithelial-mesenchymal transition phenotype in human breast cancer cells Oncogene 28 2009 2940 2947
-
(2009)
Oncogene
, vol.28
, pp. 2940-2947
-
-
Sullivan, N.J.1
Sasser, A.K.2
Axel, A.E.3
Vesuna, F.4
Raman, V.5
Ramirez, N.6
-
64
-
-
84055207487
-
IL-6 promotes head and neck tumor metastasis by inducing epithelial-mesenchymal transition via the JAK-STAT3-SNAIL signaling pathway
-
A. Yadav, B. Kumar, J. Datta, T.N. Teknos, and P. Kumar IL-6 promotes head and neck tumor metastasis by inducing epithelial-mesenchymal transition via the JAK-STAT3-SNAIL signaling pathway Mol. Cancer Res. 9 2011 1658 1667
-
(2011)
Mol. Cancer Res.
, vol.9
, pp. 1658-1667
-
-
Yadav, A.1
Kumar, B.2
Datta, J.3
Teknos, T.N.4
Kumar, P.5
-
65
-
-
84899114827
-
Widespread FRA1-dependent control of mesenchymal transdifferentiation programs in colorectal cancer cells
-
J. Diesch, E. Sanij, O. Gilan, C. Love, H. Tran, N.I. Fleming, and et al. Widespread FRA1-dependent control of mesenchymal transdifferentiation programs in colorectal cancer cells PLOS ONE 9 2014 e88950
-
(2014)
PLOS ONE
, vol.9
, pp. e88950
-
-
Diesch, J.1
Sanij, E.2
Gilan, O.3
Love, C.4
Tran, H.5
Fleming, N.I.6
-
66
-
-
84927628854
-
Aberrantly expressed Fra-1 by IL-6/STAT3 transactivation promotes colorectal cancer aggressiveness through epithelial-mesenchymal transition
-
H. Liu, G. Ren, T. Wang, Y. Chen, C. Gong, Y. Bai, and et al. Aberrantly expressed Fra-1 by IL-6/STAT3 transactivation promotes colorectal cancer aggressiveness through epithelial-mesenchymal transition Carcinogenesis 36 2015 459 468
-
(2015)
Carcinogenesis
, vol.36
, pp. 459-468
-
-
Liu, H.1
Ren, G.2
Wang, T.3
Chen, Y.4
Gong, C.5
Bai, Y.6
-
67
-
-
0030046481
-
Interleukin 6 induces the expression of vascular endothelial growth factor
-
T. Cohen, D. Nahari, L.W. Cerem, G. Neufeld, and B.Z. Levi Interleukin 6 induces the expression of vascular endothelial growth factor J. Biol. Chem. 271 1996 736 741
-
(1996)
J. Biol. Chem.
, vol.271
, pp. 736-741
-
-
Cohen, T.1
Nahari, D.2
Cerem, L.W.3
Neufeld, G.4
Levi, B.Z.5
-
68
-
-
79953183679
-
IL-6 increases MMP-13 expression and motility in human chondrosarcoma cells
-
C.H. Tang, C.F. Chen, W.M. Chen, and Y.C. Fong IL-6 increases MMP-13 expression and motility in human chondrosarcoma cells J. Biol. Chem. 286 2011 11056 11066
-
(2011)
J. Biol. Chem.
, vol.286
, pp. 11056-11066
-
-
Tang, C.H.1
Chen, C.F.2
Chen, W.M.3
Fong, Y.C.4
-
69
-
-
79954570471
-
IL6-STAT3-HIF signaling and therapeutic response to the angiogenesis inhibitor sunitinib in ovarian clear cell cancer
-
M.S. Anglesio, J. George, H. Kulbe, M. Friedlander, D. Rischin, C. Lemech, and et al. IL6-STAT3-HIF signaling and therapeutic response to the angiogenesis inhibitor sunitinib in ovarian clear cell cancer Clin. Cancer Res. 17 2011 2538 2548
-
(2011)
Clin. Cancer Res.
, vol.17
, pp. 2538-2548
-
-
Anglesio, M.S.1
George, J.2
Kulbe, H.3
Friedlander, M.4
Rischin, D.5
Lemech, C.6
-
70
-
-
84872681084
-
Interleukin-6 induces vascular endothelial growth factor expression and promotes angiogenesis through apoptosis signal-regulating kinase 1 in human osteosarcoma
-
H.E. Tzeng, C.H. Tsai, Z.L. Chang, C.M. Su, S.W. Wang, W.L. Hwang, and et al. Interleukin-6 induces vascular endothelial growth factor expression and promotes angiogenesis through apoptosis signal-regulating kinase 1 in human osteosarcoma Biochem. Pharmacol. 85 2013 531 540
-
(2013)
Biochem. Pharmacol.
, vol.85
, pp. 531-540
-
-
Tzeng, H.E.1
Tsai, C.H.2
Chang, Z.L.3
Su, C.M.4
Wang, S.W.5
Hwang, W.L.6
-
71
-
-
33749336430
-
Interleukin 6, a nuclear factor-kappaB target, predicts resistance to docetaxel in hormone-independent prostate cancer and nuclear factor-kappaB inhibition by PS-1145 enhances docetaxel antitumor activity
-
J. Domingo-Domenech, C. Oliva, A. Rovira, J. Codony-Servat, M. Bosch, X. Filella, and et al. Interleukin 6, a nuclear factor-kappaB target, predicts resistance to docetaxel in hormone-independent prostate cancer and nuclear factor-kappaB inhibition by PS-1145 enhances docetaxel antitumor activity Clin. Cancer Res. 12 2006 5578 5586
-
(2006)
Clin. Cancer Res.
, vol.12
, pp. 5578-5586
-
-
Domingo-Domenech, J.1
Oliva, C.2
Rovira, A.3
Codony-Servat, J.4
Bosch, M.5
Filella, X.6
-
72
-
-
84909987265
-
Interleukin 6 augments lung cancer chemotherapeutic resistance via ataxia-telangiectasia mutated/NF-kappaB pathway activation
-
H.Q. Yan, X.B. Huang, S.Z. Ke, Y.N. Jiang, Y.H. Zhang, Y.N. Wang, and et al. Interleukin 6 augments lung cancer chemotherapeutic resistance via ataxia-telangiectasia mutated/NF-kappaB pathway activation Cancer Sci. 105 2014 1220 1227
-
(2014)
Cancer Sci.
, vol.105
, pp. 1220-1227
-
-
Yan, H.Q.1
Huang, X.B.2
Ke, S.Z.3
Jiang, Y.N.4
Zhang, Y.H.5
Wang, Y.N.6
-
73
-
-
84888393766
-
Autocrine production of interleukin-6 confers ovarian cancer cells resistance to tamoxifen via ER isoforms and SRC-1
-
Y. Wang, Y. Qu, X.L. Zhang, J. Xing, X.L. Niu, X. Chen, and et al. Autocrine production of interleukin-6 confers ovarian cancer cells resistance to tamoxifen via ER isoforms and SRC-1 Mol. Cell. Endocrinol. 382 2014 791 803
-
(2014)
Mol. Cell. Endocrinol.
, vol.382
, pp. 791-803
-
-
Wang, Y.1
Qu, Y.2
Zhang, X.L.3
Xing, J.4
Niu, X.L.5
Chen, X.6
-
74
-
-
84906814857
-
IL-6 secreted by cancer-associated fibroblasts induces tamoxifen resistance in luminal breast cancer
-
X. Sun, Y. Mao, J. Wang, L. Zu, M. Hao, G. Cheng, and et al. IL-6 secreted by cancer-associated fibroblasts induces tamoxifen resistance in luminal breast cancer Oncogene 2014 10.1038/onc.2014.158
-
(2014)
Oncogene
-
-
Sun, X.1
Mao, Y.2
Wang, J.3
Zu, L.4
Hao, M.5
Cheng, G.6
-
75
-
-
0024459013
-
Pathogenic significance of interleukin-6 (IL-6/BSF-2) in Castleman's disease
-
K. Yoshizaki, T. Matsuda, N. Nishimoto, T. Kuritani, L. Taeho, K. Aozasa, and et al. Pathogenic significance of interleukin-6 (IL-6/BSF-2) in Castleman's disease Blood 74 1989 1360 1367
-
(1989)
Blood
, vol.74
, pp. 1360-1367
-
-
Yoshizaki, K.1
Matsuda, T.2
Nishimoto, N.3
Kuritani, T.4
Taeho, L.5
Aozasa, K.6
-
76
-
-
0033959608
-
Improvement in Castleman's disease by humanized anti-interleukin-6 receptor antibody therapy
-
N. Nishimoto, M. Sasai, Y. Shima, M. Nakagawa, T. Matsumoto, T. Shirai, and et al. Improvement in Castleman's disease by humanized anti-interleukin-6 receptor antibody therapy Blood 95 2000 56 61
-
(2000)
Blood
, vol.95
, pp. 56-61
-
-
Nishimoto, N.1
Sasai, M.2
Shima, Y.3
Nakagawa, M.4
Matsumoto, T.5
Shirai, T.6
-
77
-
-
1942485431
-
Chinese herbs as immunomodulators and potential disease-modifying antirheumatic drugs in autoimmune disorders
-
L.J. Ho, and J.H. Lai Chinese herbs as immunomodulators and potential disease-modifying antirheumatic drugs in autoimmune disorders Curr. Drug Metab. 5 2004 181 192
-
(2004)
Curr. Drug Metab.
, vol.5
, pp. 181-192
-
-
Ho, L.J.1
Lai, J.H.2
-
78
-
-
0029060421
-
Interleukin-6 (IL-6) induces the proliferation of synovial fibroblastic cells in the presence of soluble IL-6 receptor
-
M. Mihara, Y. Moriya, T. Kishimoto, and Y. Ohsugi Interleukin-6 (IL-6) induces the proliferation of synovial fibroblastic cells in the presence of soluble IL-6 receptor Br. J. Rheumatol. 34 1995 321 325
-
(1995)
Br. J. Rheumatol.
, vol.34
, pp. 321-325
-
-
Mihara, M.1
Moriya, Y.2
Kishimoto, T.3
Ohsugi, Y.4
-
79
-
-
84921465148
-
Small-molecule inhibitors for autoimmune arthritis: Success, failure and the future
-
L.J. Ho, and J.H. Lai Small-molecule inhibitors for autoimmune arthritis: success, failure and the future Eur. J. Pharmacol. 747 2015 200 205
-
(2015)
Eur. J. Pharmacol.
, vol.747
, pp. 200-205
-
-
Ho, L.J.1
Lai, J.H.2
-
80
-
-
84929023302
-
Rheumatoid arthritis therapy reappraisal: Strategies, opportunities and challenges
-
J.S. Smolen, and D. Aletaha Rheumatoid arthritis therapy reappraisal: strategies, opportunities and challenges Nat. Rev. Rheumatol. 2015 10.1038/nrrheum.2015.8
-
(2015)
Nat. Rev. Rheumatol.
-
-
Smolen, J.S.1
Aletaha, D.2
-
81
-
-
2642558925
-
Treatment of rheumatoid arthritis with humanized anti-interleukin-6 receptor antibody: A multicenter, double-blind, placebo-controlled trial
-
N. Nishimoto, K. Yoshizaki, N. Miyasaka, K. Yamamoto, S. Kawai, T. Takeuchi, and et al. Treatment of rheumatoid arthritis with humanized anti-interleukin-6 receptor antibody: a multicenter, double-blind, placebo-controlled trial Arthritis Rheum. 50 2004 1761 1769
-
(2004)
Arthritis Rheum.
, vol.50
, pp. 1761-1769
-
-
Nishimoto, N.1
Yoshizaki, K.2
Miyasaka, N.3
Yamamoto, K.4
Kawai, S.5
Takeuchi, T.6
-
82
-
-
34447300492
-
Study of active controlled monotherapy used for rheumatoid arthritis, an IL-6 inhibitor (SAMURAI): Evidence of clinical and radiographic benefit from an X ray reader-blinded randomised controlled trial of tocilizumab
-
N. Nishimoto, J. Hashimoto, N. Miyasaka, K. Yamamoto, S. Kawai, T. Takeuchi, and et al. Study of active controlled monotherapy used for rheumatoid arthritis, an IL-6 inhibitor (SAMURAI): evidence of clinical and radiographic benefit from an X ray reader-blinded randomised controlled trial of tocilizumab Ann. Rheum. Dis. 66 2007 1162 1167
-
(2007)
Ann. Rheum. Dis.
, vol.66
, pp. 1162-1167
-
-
Nishimoto, N.1
Hashimoto, J.2
Miyasaka, N.3
Yamamoto, K.4
Kawai, S.5
Takeuchi, T.6
-
83
-
-
84871093047
-
Adding tocilizumab or switching to tocilizumab monotherapy in methotrexate inadequate responders: 24-week symptomatic and structural results of a 2-year randomised controlled strategy trial in rheumatoid arthritis (ACT-RAY)
-
M. Dougados, K. Kissel, T. Sheeran, P.P. Tak, P.G. Conaghan, E.M. Mola, and et al. Adding tocilizumab or switching to tocilizumab monotherapy in methotrexate inadequate responders: 24-week symptomatic and structural results of a 2-year randomised controlled strategy trial in rheumatoid arthritis (ACT-RAY) Ann. Rheum. Dis. 72 2013 43 50
-
(2013)
Ann. Rheum. Dis.
, vol.72
, pp. 43-50
-
-
Dougados, M.1
Kissel, K.2
Sheeran, T.3
Tak, P.P.4
Conaghan, P.G.5
Mola, E.M.6
-
84
-
-
84923550944
-
Catch-up growth during tocilizumab therapy for systemic juvenile idiopathic arthritis: Results from a phase III trial
-
F. De Benedetti, H. Brunner, N. Ruperto, R. Schneider, R. Xavier, R. Allen, and et al. Catch-up growth during tocilizumab therapy for systemic juvenile idiopathic arthritis: results from a phase III trial Arthritis Rheumatol. 67 2015 840 848
-
(2015)
Arthritis Rheumatol.
, vol.67
, pp. 840-848
-
-
De Benedetti, F.1
Brunner, H.2
Ruperto, N.3
Schneider, R.4
Xavier, R.5
Allen, R.6
-
85
-
-
84901594789
-
Efficacy of tocilizumab in conventional treatment-refractory adult-onset Still's disease: Multicenter retrospective open-label study of thirty-four patients
-
F. Ortiz-Sanjuan, R. Blanco, V. Calvo-Rio, J. Narvaez, E. Rubio Romero, A. Olive, and et al. Efficacy of tocilizumab in conventional treatment-refractory adult-onset Still's disease: multicenter retrospective open-label study of thirty-four patients Arthritis Rheumatol. 66 2014 1659 1665
-
(2014)
Arthritis Rheumatol.
, vol.66
, pp. 1659-1665
-
-
Ortiz-Sanjuan, F.1
Blanco, R.2
Calvo-Rio, V.3
Narvaez, J.4
Rubio Romero, E.5
Olive, A.6
-
86
-
-
84880753128
-
Therapies for active rheumatoid arthritis after methotrexate failure
-
J.R. O'Dell, T.R. Mikuls, T.H. Taylor, V. Ahluwalia, M. Brophy, S.R. Warren, and et al. Therapies for active rheumatoid arthritis after methotrexate failure N. Engl. J. Med. 369 2013 307 318
-
(2013)
N. Engl. J. Med.
, vol.369
, pp. 307-318
-
-
O'Dell, J.R.1
Mikuls, T.R.2
Taylor, T.H.3
Ahluwalia, V.4
Brophy, M.5
Warren, S.R.6
-
87
-
-
84902347606
-
Targeting IL-6 for the treatment of rheumatoid arthritis: Phase II investigational drugs
-
L. Semerano, A. Thiolat, E. Minichiello, G. Clavel, N. Bessis, and M.C. Boissier Targeting IL-6 for the treatment of rheumatoid arthritis: phase II investigational drugs Expert Opin. Investig. Drugs 23 2014 979 999
-
(2014)
Expert Opin. Investig. Drugs
, vol.23
, pp. 979-999
-
-
Semerano, L.1
Thiolat, A.2
Minichiello, E.3
Clavel, G.4
Bessis, N.5
Boissier, M.C.6
-
88
-
-
84899708467
-
Discovery and characterization of olokizumab: A humanized antibody targeting interleukin-6 and neutralizing gp130-signaling
-
S. Shaw, T. Bourne, C. Meier, B. Carrington, R. Gelinas, A. Henry, and et al. Discovery and characterization of olokizumab: a humanized antibody targeting interleukin-6 and neutralizing gp130-signaling mAbs 6 2014 774 782
-
(2014)
MAbs
, vol.6
, pp. 774-782
-
-
Shaw, S.1
Bourne, T.2
Meier, C.3
Carrington, B.4
Gelinas, R.5
Henry, A.6
-
89
-
-
84905164026
-
Sirukumab, a human anti-interleukin-6 monoclonal antibody: A randomised, 2-part (proof-of-concept and dose-finding), phase II study in patients with active rheumatoid arthritis despite methotrexate therapy
-
J.S. Smolen, M.E. Weinblatt, S. Sheng, Y. Zhuang, and B. Hsu Sirukumab, a human anti-interleukin-6 monoclonal antibody: a randomised, 2-part (proof-of-concept and dose-finding), phase II study in patients with active rheumatoid arthritis despite methotrexate therapy Ann. Rheum. Dis. 73 2014 1616 1625
-
(2014)
Ann. Rheum. Dis.
, vol.73
, pp. 1616-1625
-
-
Smolen, J.S.1
Weinblatt, M.E.2
Sheng, S.3
Zhuang, Y.4
Hsu, B.5
-
90
-
-
83255176682
-
Randomised phase II study of siltuximab (CNTO 328), an anti-IL-6 monoclonal antibody, in combination with mitoxantrone/prednisone versus mitoxantrone/prednisone alone in metastatic castration-resistant prostate cancer
-
K. Fizazi, J.S. De Bono, A. Flechon, A. Heidenreich, E. Voog, N.B. Davis, and et al. Randomised phase II study of siltuximab (CNTO 328), an anti-IL-6 monoclonal antibody, in combination with mitoxantrone/prednisone versus mitoxantrone/prednisone alone in metastatic castration-resistant prostate cancer Eur. J. Cancer 48 2012 85 93
-
(2012)
Eur. J. Cancer
, vol.48
, pp. 85-93
-
-
Fizazi, K.1
De Bono, J.S.2
Flechon, A.3
Heidenreich, A.4
Voog, E.5
Davis, N.B.6
-
91
-
-
84862783578
-
A phase II, double-blind, randomised, placebo-controlled study of BMS945429 (ALD518) in patients with rheumatoid arthritis with an inadequate response to methotrexate
-
P. Mease, V. Strand, L. Shalamberidze, A. Dimic, T. Raskina, L.A. Xu, and et al. A phase II, double-blind, randomised, placebo-controlled study of BMS945429 (ALD518) in patients with rheumatoid arthritis with an inadequate response to methotrexate Ann. Rheum. Dis. 71 2012 1183 1189
-
(2012)
Ann. Rheum. Dis.
, vol.71
, pp. 1183-1189
-
-
Mease, P.1
Strand, V.2
Shalamberidze, L.3
Dimic, A.4
Raskina, T.5
Xu, L.A.6
-
92
-
-
84905179575
-
Sarilumab, a fully human monoclonal antibody against IL-6Ralpha in patients with rheumatoid arthritis and an inadequate response to methotrexate: Efficacy and safety results from the randomised SARIL-RA-MOBILITY Part A trial
-
T.W. Huizinga, R.M. Fleischmann, M. Jasson, A.R. Radin, J. van Adelsberg, S. Fiore, and et al. Sarilumab, a fully human monoclonal antibody against IL-6Ralpha in patients with rheumatoid arthritis and an inadequate response to methotrexate: efficacy and safety results from the randomised SARIL-RA-MOBILITY Part A trial Ann. Rheum. Dis. 73 2014 1626 1634
-
(2014)
Ann. Rheum. Dis.
, vol.73
, pp. 1626-1634
-
-
Huizinga, T.W.1
Fleischmann, R.M.2
Jasson, M.3
Radin, A.R.4
Van Adelsberg, J.5
Fiore, S.6
-
93
-
-
70450238013
-
Inhibition of interleukin-6-transsignaling via gp130-Fc in hemorrhagic shock and sepsis
-
S.T. Mees, S. Toellner, K. Marx, F. Faendrich, K.J. Kallen, J. Schroeder, and et al. Inhibition of interleukin-6-transsignaling via gp130-Fc in hemorrhagic shock and sepsis J. Surg. Res. 157 2009 235 242
-
(2009)
J. Surg. Res.
, vol.157
, pp. 235-242
-
-
Mees, S.T.1
Toellner, S.2
Marx, K.3
Faendrich, F.4
Kallen, K.J.5
Schroeder, J.6
-
94
-
-
84905192115
-
Efficacy and safety of olokizumab in patients with rheumatoid arthritis with an inadequate response to TNF inhibitor therapy: Outcomes of a randomised phase IIb study
-
M.C. Genovese, R. Fleischmann, D. Furst, N. Janssen, J. Carter, B. Dasgupta, and et al. Efficacy and safety of olokizumab in patients with rheumatoid arthritis with an inadequate response to TNF inhibitor therapy: outcomes of a randomised phase IIb study Ann. Rheum. Dis. 73 2014 1607 1615
-
(2014)
Ann. Rheum. Dis.
, vol.73
, pp. 1607-1615
-
-
Genovese, M.C.1
Fleischmann, R.2
Furst, D.3
Janssen, N.4
Carter, J.5
Dasgupta, B.6
-
95
-
-
84929881847
-
Sarilumab plus methotrexate in patients with active rheumatoid arthritis and inadequate response to methotrexate: Results of a phase III study
-
M.C. Genovese, R. Fleischmann, A. Kivitz, M. Rell-Bakalarska, R. Martincova, S. Fiore, and et al. Sarilumab plus methotrexate in patients with active rheumatoid arthritis and inadequate response to methotrexate: results of a phase III study Arthritis Rheumatol. 2015 10.1002/art.39093
-
(2015)
Arthritis Rheumatol.
-
-
Genovese, M.C.1
Fleischmann, R.2
Kivitz, A.3
Rell-Bakalarska, M.4
Martincova, R.5
Fiore, S.6
-
96
-
-
84931575213
-
Inhibition of IL-6 signaling significantly reduces primary tumor growth and recurrencies in orthotopic xenograft models of pancreatic cancer
-
F.A. Goumas, R. Holmer, J.H. Egberts, A. Gontarewicz, C. Heneweer, U. Geisen, and et al. Inhibition of IL-6 signaling significantly reduces primary tumor growth and recurrencies in orthotopic xenograft models of pancreatic cancer Int. J. Cancer 2015 10.1002/ijc.29445
-
(2015)
Int. J. Cancer
-
-
Goumas, F.A.1
Holmer, R.2
Egberts, J.H.3
Gontarewicz, A.4
Heneweer, C.5
Geisen, U.6
-
97
-
-
84898967209
-
A phase I/II, multiple-dose, dose-escalation study of siltuximab, an anti-interleukin-6 monoclonal antibody, in patients with advanced solid tumors
-
E. Angevin, J. Tabernero, E. Elez, S.J. Cohen, R. Bahleda, J.L. van Laethem, and et al. A phase I/II, multiple-dose, dose-escalation study of siltuximab, an anti-interleukin-6 monoclonal antibody, in patients with advanced solid tumors Clin. Cancer Res. 20 2014 2192 2204
-
(2014)
Clin. Cancer Res.
, vol.20
, pp. 2192-2204
-
-
Angevin, E.1
Tabernero, J.2
Elez, E.3
Cohen, S.J.4
Bahleda, R.5
Van Laethem, J.L.6
-
98
-
-
77957995258
-
A phase I/II study of siltuximab (CNTO 328), an anti-interleukin-6 monoclonal antibody, in metastatic renal cell cancer
-
J.F. Rossi, S. Negrier, N.D. James, I. Kocak, R. Hawkins, H. Davis, and et al. A phase I/II study of siltuximab (CNTO 328), an anti-interleukin-6 monoclonal antibody, in metastatic renal cell cancer Br. J. Cancer 103 2010 1154 1162
-
(2010)
Br. J. Cancer
, vol.103
, pp. 1154-1162
-
-
Rossi, J.F.1
Negrier, S.2
James, N.D.3
Kocak, I.4
Hawkins, R.5
Davis, H.6
-
99
-
-
77953091816
-
Clinical and correlative results of SWOG S0354: A phase II trial of CNTO328 (siltuximab), a monoclonal antibody against interleukin-6, in chemotherapy-pretreated patients with castration-resistant prostate cancer
-
T.B. Dorff, B. Goldman, J.K. Pinski, P.C. Mack, P.N. Lara Jr., P.J. Van Veldhuizen Jr., and et al. Clinical and correlative results of SWOG S0354: a phase II trial of CNTO328 (siltuximab), a monoclonal antibody against interleukin-6, in chemotherapy-pretreated patients with castration-resistant prostate cancer Clin. Cancer Res. 16 2010 3028 3034
-
(2010)
Clin. Cancer Res.
, vol.16
, pp. 3028-3034
-
-
Dorff, T.B.1
Goldman, B.2
Pinski, J.K.3
Mack, P.C.4
Lara, P.N.5
Van Veldhuizen, P.J.6
-
100
-
-
84919683208
-
A phase 2, randomized, double-blind, placebo-controlled study of siltuximab (anti-IL-6 mAb) and bortezomib versus bortezomib alone in patients with relapsed or refractory multiple myeloma
-
R.Z. Orlowski, L. Gercheva, C. Williams, H. Sutherland, T. Robak, T. Masszi, and et al. A phase 2, randomized, double-blind, placebo-controlled study of siltuximab (anti-IL-6 mAb) and bortezomib versus bortezomib alone in patients with relapsed or refractory multiple myeloma Am. J. Hematol. 90 2015 42 49
-
(2015)
Am. J. Hematol.
, vol.90
, pp. 42-49
-
-
Orlowski, R.Z.1
Gercheva, L.2
Williams, C.3
Sutherland, H.4
Robak, T.5
Masszi, T.6
-
101
-
-
4043176334
-
IL-6 as an intracrine growth factor for renal carcinoma cell lines
-
L. Alberti, M.C. Thomachot, T. Bachelot, C. Menetrier-Caux, I. Puisieux, and J.Y. Blay IL-6 as an intracrine growth factor for renal carcinoma cell lines Int. J. Cancer 111 2004 653 661
-
(2004)
Int. J. Cancer
, vol.111
, pp. 653-661
-
-
Alberti, L.1
Thomachot, M.C.2
Bachelot, T.3
Menetrier-Caux, C.4
Puisieux, I.5
Blay, J.Y.6
-
102
-
-
69249087671
-
Environment-mediated drug resistance: A major contributor to minimal residual disease
-
M.B. Meads, R.A. Gatenby, and W.S. Dalton Environment-mediated drug resistance: a major contributor to minimal residual disease Nat. Rev. Cancer 9 2009 665 674
-
(2009)
Nat. Rev. Cancer
, vol.9
, pp. 665-674
-
-
Meads, M.B.1
Gatenby, R.A.2
Dalton, W.S.3
-
104
-
-
70349402169
-
Long-term safety and efficacy of tocilizumab, an anti-IL-6 receptor monoclonal antibody, in monotherapy, in patients with rheumatoid arthritis (the STREAM study): Evidence of safety and efficacy in a 5-year extension study
-
N. Nishimoto, N. Miyasaka, K. Yamamoto, S. Kawai, T. Takeuchi, and J. Azuma Long-term safety and efficacy of tocilizumab, an anti-IL-6 receptor monoclonal antibody, in monotherapy, in patients with rheumatoid arthritis (the STREAM study): evidence of safety and efficacy in a 5-year extension study Ann. Rheum. Dis. 68 2009 1580 1584
-
(2009)
Ann. Rheum. Dis.
, vol.68
, pp. 1580-1584
-
-
Nishimoto, N.1
Miyasaka, N.2
Yamamoto, K.3
Kawai, S.4
Takeuchi, T.5
Azuma, J.6
-
105
-
-
84891795508
-
Effectiveness and safety of tocilizumab: Postmarketing surveillance of 7901 patients with rheumatoid arthritis in Japan
-
T. Koike, M. Harigai, S. Inokuma, N. Ishiguro, J. Ryu, T. Takeuchi, and et al. Effectiveness and safety of tocilizumab: postmarketing surveillance of 7901 patients with rheumatoid arthritis in Japan J. Rheumatol. 41 2014 15 23
-
(2014)
J. Rheumatol.
, vol.41
, pp. 15-23
-
-
Koike, T.1
Harigai, M.2
Inokuma, S.3
Ishiguro, N.4
Ryu, J.5
Takeuchi, T.6
-
106
-
-
28644436100
-
Multivalent avimer proteins evolved by exon shuffling of a family of human receptor domains
-
J. Silverman, Q. Liu, A. Bakker, W. To, A. Duguay, B.M. Alba, and et al. Multivalent avimer proteins evolved by exon shuffling of a family of human receptor domains Nat. Biotechnol. 23 2005 1556 1561
-
(2005)
Nat. Biotechnol.
, vol.23
, pp. 1556-1561
-
-
Silverman, J.1
Liu, Q.2
Bakker, A.3
To, W.4
Duguay, A.5
Alba, B.M.6
-
109
-
-
84907938432
-
Mutational approaches to improve the biophysical properties of human single-domain antibodies
-
D.Y. Kim, G. Hussack, H. Kandalaft, and J. Tanha Mutational approaches to improve the biophysical properties of human single-domain antibodies Biochim. Biophys. Acta 1844 2014 1983 2001
-
(2014)
Biochim. Biophys. Acta
, vol.1844
, pp. 1983-2001
-
-
Kim, D.Y.1
Hussack, G.2
Kandalaft, H.3
Tanha, J.4
-
110
-
-
80051668855
-
Whole-molecule antibody engineering: Generation of a high-affinity anti-IL-6 antibody with extended pharmacokinetics
-
D.K. Finch, M.A. Sleeman, J. Moisan, F. Ferraro, S. Botterell, J. Campbell, and et al. Whole-molecule antibody engineering: generation of a high-affinity anti-IL-6 antibody with extended pharmacokinetics J. Mol. Biol. 411 2011 791 807
-
(2011)
J. Mol. Biol.
, vol.411
, pp. 791-807
-
-
Finch, D.K.1
Sleeman, M.A.2
Moisan, J.3
Ferraro, F.4
Botterell, S.5
Campbell, J.6
-
112
-
-
84896996881
-
Chemically modified DNA aptamers bind interleukin-6 with high affinity and inhibit signaling by blocking its interaction with interleukin-6 receptor
-
S. Gupta, M. Hirota, S.M. Waugh, I. Murakami, T. Suzuki, M. Muraguchi, and et al. Chemically modified DNA aptamers bind interleukin-6 with high affinity and inhibit signaling by blocking its interaction with interleukin-6 receptor J. Biol. Chem. 289 2014 8706 8719
-
(2014)
J. Biol. Chem.
, vol.289
, pp. 8706-8719
-
-
Gupta, S.1
Hirota, M.2
Waugh, S.M.3
Murakami, I.4
Suzuki, T.5
Muraguchi, M.6
-
113
-
-
84901649576
-
Hyaluronate-gold nanoparticle/tocilizumab complex for the treatment of rheumatoid arthritis
-
H. Lee, M.Y. Lee, S.H. Bhang, B.S. Kim, Y.S. Kim, J.H. Ju, and et al. Hyaluronate-gold nanoparticle/tocilizumab complex for the treatment of rheumatoid arthritis ACS Nano 8 2014 4790 4798
-
(2014)
ACS Nano
, vol.8
, pp. 4790-4798
-
-
Lee, H.1
Lee, M.Y.2
Bhang, S.H.3
Kim, B.S.4
Kim, Y.S.5
Ju, J.H.6
|